The next focusIR Investor Webinar takes places on 14th May with guest speakers from WS Blue Whale Growth Fund, Taseko Mines, Kavango Resources and CQS Natural Resources fund. Please register here.
London South East prides itself on its community spirit, and in order to keep the chat section problem free, we ask all members to follow these simple rules. In these rules, we refer to ourselves as "we", "us", "our". The user of the website is referred to as "you" and "your".
By posting on our share chat boards you are agreeing to the following:
The IP address of all posts is recorded to aid in enforcing these conditions. As a user you agree to any information you have entered being stored in a database. You agree that we have the right to remove, edit, move or close any topic or board at any time should we see fit. You agree that we have the right to remove any post without notice. You agree that we have the right to suspend your account without notice.
Please note some users may not behave properly and may post content that is misleading, untrue or offensive.
It is not possible for us to fully monitor all content all of the time but where we have actually received notice of any content that is potentially misleading, untrue, offensive, unlawful, infringes third party rights or is potentially in breach of these terms and conditions, then we will review such content, decide whether to remove it from this website and act accordingly.
Premium Members are members that have a premium subscription with London South East. You can subscribe here.
London South East does not endorse such members, and posts should not be construed as advice and represent the opinions of the authors, not those of London South East Ltd, or its affiliates.
Welcome. These chat boards, at their best, are for sharing ideas but also for helping one another when we can, IMO.
Thanks for the update LW and for keeping us in the loop.
I got an email from IR a week after my question. I only checked that account yesterday, as I had pretty much given up on getting a response. The response asked me which conference in particular!
So followed up...only to get an out of office reply! I sent the link in question (even though I had already mentioned this in the original email) and will come back when they do me. Maybe before we are all pushing up the daisies :) Should have contacted Iain direct. Hey ho.
...
the exosomes are incredibly small (and that's coming from a microscopist!) so manipulating these is difficult – it has taken years and the pharma industry will take several more to figure out various techniques and to develop instrumentation in order to eventually set industry standards. however, things are moving fast in this area.
the company has recently (see the latest rns) proved in vivo tissue targeting by exosomes produced by the company's immortalised cell lines using animal models. it's my understanding that there were three separate in vivo experimental arms carried out over the first half of 2023. two were successful whilst the third was ****ed up and had to be repeated. iain said during the agm that the repeated arm was expected to be completed at the end of september beginning of october (ie about now). i don't know any details of the experiments, but the rns was released 4th september, relatively early, so i surmise either, a) they got a wiggle on, or, b) the last arm was ****ed up again but non-essential to prove the case of targeting, or, c) they looked at a different aspect – such as loading exosomes then transporting the payload to a target tissue – which is obviously the ultimate goal...and pot of gold. this may or may not have worked, but it should in principle.
i'm relaxed about the conference no-show; i suspect the conference appearance was arranged way before the complicated in vivo experiments had concluded. i don't think it was ever advertised on reneuron's website either.
Hi Fred,
Here's my take on the current situation.
First, some historical context; Reneuron have gone from aiming to treat single disease indications (requiring long and expensive trials, in our case for stroke and RP) to a platform technology. Expensive trials can kill small biotechs...see Codiak. Chucking stem cells/pre-cursor cells loosely in to an area and hoping they magically self organise and survive, we now know, was asking too much of the little cellular blighters. They were best guesses at the time, so I can't fault them for at least trying. We have learned that putting a baby in an old people's home does not make everyone in it young again! But the science has moved forward rapidly since. Who knew 20 years ago that there was a cell-to-cell communication network that pre-dates the rise of multi-cellular organisms or that cellular clocks could be reversed?
The company's m.o. has mutated into providing shuttlebuses aka exosomes for potentially pre-existing and new therapeutic payloads to specific structures in the body. Why is this homing to certain areas so important? Many many drug trials have failed and will continue to fail due to off-target toxicity. So many Phase 1, 2, & 3 trials have flunked – think of the lost lives, billions of dollars and personal reputations ruined over the decades because of adverse events during trials. The sad thing is that many therapeutic molecules themselves were shown to be very effective at treating the diseased cells in vitro but this came at a too higher price in terms of side effects (toxicity) when put in to human volunteers. What if some of these drugs/molecules could be sent exclusively to their intended target? That's a very big win if it can be pulled off...and why I'm interested in this company.
Reneuron's history in stem cell technology is not a complete waste of time and effort, far from it, imo. They have a stem cell line that has been immortalised and can give rise to many pre-cursor cell lines which are, in turn, immortal. Without this immortalisation cellular aging issues will likely kick in and screw things up. I suspect many other stem cell candidates do not have this valuable characteristic. They have also been shown via stem cell implantation to be safe in humans (stroke and RP trials) which is obviously an important consideration for therapy credibility when considered by a regulatory body.
It's at the pre-cursor cell point at which specificity (ie. tissue targeting) comes in to play. These need to produce, amongst other things, a consistent and reliable output (of homing exosomes) in order to be considered by pharma for industrial processes and reliable treatments. That is why the immortalised cell IP is necessary and so valuable along with the tissue targeting properties. Both are essential in my view.
continued....
Welcome back Freddieboy.
The same problem exists today that existed when you last left in that the company has a potential product in exosomes, but as yet it hasn't been realized.
There was an RNS on exosomes and proof of concept invitro and that the next stage of delivery of drugs to specific parts of a body in large enough quantities to be effective was going to begin.
There was going to be an announcement at a conference and then it suddenly all went quiet, and nobody knows why.
This where we all are now.
P.S, I think the company runs out of money in April. Good luck.
Welcome back Fred. There’s been successor optimists but none with your dispositional level, altho with similar levels of prophetic skills. Since you left we’ve also lost your nemesis, Purpleachy, so will your return result in Purps resurrection too?
I’m sure the optimists will give you a heads up, and Purp, if he/she is around will no doubt provide appropriate checks and balances.
Your return will also no doubt once again raise the question, has Fred and Mr Woodford ever been seen in the same room together 😀Anyway good to hear from you. Good luck if you ultimately invest. There’s a lot of us with fingers and everything else crossed.
I sold out a few years ago when we found out the stroke treatment couldn't be verified as due to stem cell treatment or the body healing itself.
As for the Retinitis Pigmentosa and using stem cell tails to deliver cancer treatments though the blood barrier membrane, it was in its infancy....John Sindon was in charge a Mr Hunt finance director.
Times moved on and have no idea what they are cooking up now and how close the boil they are. One things for certain the sp appears to have taken a hammering and I could consider reinvesting.
Would one of you kind gents/Ladies bring me up to speed on the current pipeline and any treatments showing short term potential....by short I don't mean a month away as infinite months is a short term target for Reneuron.
I'd prefer to hear what investors are expecting as against the company Bull..
Sincerely Fred
Makes sense, thanks!
Because the trade price sits closer to the bid than the ask .
Pretty sure 1st 4 trades @6.24 ish are buys, one of which was mine! Why are LSE listing them wrong, I wonder?
Nope. Not even a generic response. I have been entertaining some guests who are staying for a few days, so if the radio silence continues, I will follow up on Monday when I have some time to do so.
They should call this company Titanic because it sure to hell going down perhaps Atra zenica might be able to make use of some of Rene, s equipment because they don, t have clue how to use it.
LW did you get a response to your email about the conference ‘no-show’? I was wondering whether Mr Ross had run out of petty-cash for the airfare or he didn’t want to be embarrassed by questions on going belly-up, or conversely whether there’s a bailout in play?
...or someone wants in cheap?
Likely to be one the aim causalities, delists ahead
That’s what normally happens, although Mr Ross failed to get one away late last year. In recent times, retail stockholders have been offered rights issue crumbs; although thank goodness for that as my losses would be even greater!
The company is fast running out of cash, and I would suggest any deal down the track will result in a deal to take part of the Equity in exchange for cash.
You have to ask, why would RENE do an enthusiastic RNS ( re- INVIVO results ) and then not attend / present at an Exosomes Industry focused conference. We're they ever listed as definite attendee ?
It can't be that their science somehow got derailed as they did that RNS at 7.00am on the 4th Sept the day before the conference.
It does feel like something is happening in the background and I'm hoping that what ever 'it' is, that it's a positive thing.
Chester.
Yes, obviously high risk but, if it comes good, any deal could be huge.
No response so far. We can only hope that there is a positive reason for that. That word again, hope. Some interesting trades recently though, so who knows?
GLA while we wait for something more concrete than hope!
Investors are hopeful that the company's long-standing commitment to research could yield positive outcomes in the future.
While it may not be of utmost importance, it's worth noting that the 10K listed as a sell was actually a purchase
As some stock up on Bud for the weekend by selling small Rene tranches, others, as we await Mr Ross’ response to LW’s email, may be conjugating variables of what the no-show could mean? But having ruminated on potential conspiracy theories, it’s probably as simple as we couldn’t afford the airline ticket!
We are certainly on thin ice territory with trust right now.